Physician profile
Smitha E Oommen
NPI 1184829764
$4,377.43
in general payments reported to CMS, 2019-2025
41 companies · $734 in 2025
The $734 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $194 · 2021: $238 · 2022: $561 · 2023: $850 · 2024: $355 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $659.74 | 2019-2025 | |
| Incyte Corporation | $437.53 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals Lp | $346.85 | 2022-2025 | Imfinzi, Calquence |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.34 | 2019-2023 | Gilotrif |
| Assertio Therapeutics, INC. | $220.29 | 2019-2020 | |
| Genentech USA, INC. | $198.25 | 2019 | |
| Daiichi Sankyo INC. | $188.59 | 2019-2024 | Enhertu |
| Glaxosmithkline, LLC. | $184.57 | 2021-2025 | Ojjaara, Blenrep |
| Puma Biotechnology, INC. | $169.15 | 2019-2024 | |
| Octapharma USA, INC. | $143.15 | 2023 | Octagam Immune Globulin (Human), Panzyga |
| Acadia Pharmaceuticals INC | $123.87 | 2019-2025 | Nuplazid |
| Springworks Therapeutics, INC. | $122.10 | 2025 | Gomekli |
| E.R. Squibb & Sons, L.L.C. | $116.16 | 2019-2023 | |
| Abbvie INC. | $108.66 | 2023-2025 | |
| Eisai INC. | $107.40 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Oommen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.